August 2017

FORWARD LOOKING STATEMENT

This presentation includes forward-looking statements, including statements regarding the Companys ability to achieve the milestones and financial
projections in the 3 and 1 in 20 plan, including 2020 revenues of $560 million, Adjusted EPS of $1.00, and $110 million in revenues from new pain
management products; the Companys ability to sustain 20%+ revenue growth over the long term; the Companys ability to deliver P&L leverage in 2017
and beyond; the Companys ability to become a leader in the surgical and ortho-biologicals market; the Companys ability to transition to a
biopharmaceutical company at an accelerated pace; the Companys continued ability to sell existing products under Section 361 of the PHSA prior to the
issuance of a BLA; the Companys ability to expand its sales force; the timing, results, and publication of clinical studies, and the potential safety and
efficacy, and additional approved uses and markets, for our products; the timing and results of INDs/BLAs; incremental commercial reimbursement
coverage, including coverage for DFUs and VLUs; the ability to obtain incremental benefits from GPO and IDN contracts, and the timing of such benefits;
the Companys ability successfully to develop new products and the timing and receipt of pending and anticipated regulatory clearances and approvals,
the timing of product launches, the size of the markets for the Companys current and future products, and the share of such markets that the Company
will be able to garner; the Companys ability to continue to increase market share, expand the markets for its products, to expand internationally, and the
timing of such actions; the Companys ability to grow operating room revenues, to hire additional sales representatives, to obtain increased GPO and IDN
coverage, to launch additional products, to acquire synergistic companies or products, and to increase demand; and the expected results of patent
litigation and inter partes reviews; and estimated 2017 revenues. Forward-looking statements also may be identified by words such as "believe," "except,"
"may," "plan," "potential," "will," goal, and similar expressions, and are based on our current beliefs and expectations.

Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements.
Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual
results to differ materially from those indicated by such forward-looking statements include the risks that the Company may be unable to transition to a
biopharmaceutical company at an accelerated pace; the Company may be unable successfully to develop anticipated new products; the timing of
anticipated regulatory clearances and approvals may be delayed or denied; adverse regulatory actions against the Company; the markets for the
Companys current and future products may not be as large as the Company projects or grow as anticipated; the Company may not be able to achieve the
market share it anticipates; the Company may face more and more effective competition, the Company may not continue to achieve significant process
improvements and efficiencies; the Company may be unable to achieve the milestones and financial projections in the 3 and 1 in 20 plan; market
demand for the Companys products may not grow or could decline; unexpected concerns may arise from additional data or analysis from our clinical
trials; regulatory submissions may take longer or be more difficult to complete than expected; and that regulatory authorities may require additional
information or further studies or may fail to approve or may delay approval or grant marketing approval that is different than anticipated; and we may be
unable to hire the expected number of sales representatives on a timely basis. For additional risks that might affect the Company, please review the Risk
Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements
speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.
2
 INVESTMENT HIGHLIGHTS

Global Company Delivering Innovative Placental Tissue Based Regenerative

Therapies and Therapeutic Biologics that Restore Function and Improve
Quality of Life
Opportunity to use a Product Under the 361 Regulations before Conducting
a BLA Trial Provides Unique Clinical Trial and Revenue Benefits

3 and 1 in 20 Strategic Plan Triples 2015 Revenues to $560M and Delivers

$1.00 of Adjusted Earnings in 2020

Sustain 20%+ Revenue Growth Over the Long Term

>85% Gross Margins and Strong Balance Sheet

Deliver P&L Leverage in 2017 and Beyond

Since May 2014, Executed $72M of a $100M Share Repurchase Program

3
 COMPANY HIGHLIGHTS

5 Innovative Technology Platforms

Over 100* Issued and Allowed Patents

Proprietary Purion Processed Placental Tissue Allograft Contains a Milieu

of 220 Proteins (Growth Factors, Chemokines and Cytokines)

Industry Leader in the Amniotic and Placental Tissue Market

Emerging Leader in the Surgical and Ortho-Biologics Market

In 2020 Complete Transition to a Biopharmaceutical Company

Existing Products Remain Regulated through Section 361 of PHSA
New Products Regulated through Section 351 of PHSA under IND/BLA
Pain Management, Respiratory Disease and Cardiovascular Disease are Large
Biopharmaceutical Opportunities

*owned and licensed

4
 EXPERIENCED MANAGEMENT TEAM
Parker H. Pete Petit William C. Taylor Michael J. Senken Alexandra O. Haden
Chairman & CEO President & COO Chief Financial Officer General Counsel

Thornton A. Kuntz Deborah L. Dean Christopher M. Cashman Mark E. Diaz

Senior Vice President, Executive Vice President Executive Vice President & Senior Vice President,
HR & Administration Chief Commercialization Officer Commercial Operations

Scott M. Turner Michael W. Carlton Kevin D. Lilly Marlene M. DeSimone

Senior Vice President, Senior Vice President, Senior Vice President, Senior Vice President,
Operations & Procurement Global Sales Sales Marketing

Dr. Rebeccah Brown Dr. Donald E. Fetterolf Dr. Thomas J. Koob Dr. I. Mark Landy
Vice President, Chief Medical Officer Chief Scientific Officer Vice President,
Global Regulatory Affairs Strategic Initiatives

5
 DELIVERING CONSISTENT SUSTAINABLE GROWTH

26 Consecutive Quarters of Sequential Revenue Growth

70 Met or Exceeded Revenue Guidance in 25 of Last 26 Quarters

60

50
$s - Millions

40

30

20

10

6
 2017 GROWTH DRIVERS

2016 New Product Launches: EpiCord, AmnioFill, OrthoFlo Lyo

Continued Sales Force Expansion
Clinical Trial Results and Publications
Incremental Commercial Reimbursement Coverage for DFU and VLU
International Expansion
Continued Leverage of GPO/IDN Contracts
5 Group Purchasing Organizations (GPO) contracts in place
- 4 have 80% or sole commitment tiers for Amniotic Tissue/Skin Substitute
- Covers approximately 4,000 hospitals
40 Integrated Delivery Networks (IDN) Contracts
- Covers approximately 1,300 hospitals
- Many have committed Amniotic Tissue Contracts

7
 5-YEAR STRATEGIC PLAN: 3 AND 1 IN 20

In 2020: Triple 2015 Revenue, Deliver $1.00 of Adjusted EPS

and Complete Transition to a Biopharmaceutical Company

2020 Assumptions
Organic Rev Growth
107.5M FDSO
*EBITDA 30%
Tax 36%

$187M $560M

Wound Care Operating Room Pain Management

* Adjusted
8
 U.S. WOUND BIOLOGICS MARKET IN 2020

2020 Skin/Dermal Substitute (SDS) Segment Sales Estimate $1.1B

2020 Amniotic Tissue Share Estimate 58% vs. 29% in 2014
2016 SDS Sales Estimate $681M up 15% vs. 2015
2016 MiMedx Amniotic Tissue Share 63%

10%
21% 17.5%

39%
2015 SDS Segment 2016 SDS Segment 44.7% 2020 SDS Segment
27%

$587M $681M $1.1B 58%

31.9%
34% 5%
6%
5.9%

Amniotic Tissue Allografts Xenografts Cell-Based Bioengineering

SmartTRAK Business Intelligence and
Company Estimates
9
 CHRONIC WOUND MARKET IS UNDERPENETRATED

1.4M Chronic DFU/VLU Wounds - $3B Mkt Opportunity Alone

2015
2016 U.S. Market Facts 6.5M US Patients have
Chronic Wounds
Annual Cost of Treating Chronic Wounds
in the U.S. is $25 Billion
Skin/Dermal Substitutes is the Largest
Segment at $681 Million 3M are non-
MiMedx is the Market Leader at 30%
healing wounds
Sales of Placenta Derived / Amniotic Tissue
Products Grew 33% to $305M
MiMedx is the Market Share Leader at 63%
Under 200K are Treated With
A Skin or Dermal Substitute

SmartTRAK Business Intelligence

10
 WOUND CARE GROWTH TARGET: 5YR 20% CAGR

Wound Care Growth Drivers

1. Continue To Take Market Share

Leverage Safety Advantage of Terminal Sterilization
Expand Scientific and Clinical Body of Evidence
Increase Lives Under Coverage
Broaden Reach In IDN / GPO Contracts
New Products
New Settings, Long-term Care (LTAC)

2. Expand The Market

Secondary City Expansion
Convert Physicians that do not
use AWC Products
Influence and Improve Referral
Patterns
Wound Care Operating Room Pain Management

3. International Expansion

11
 EPIFIX VLU MULTICENTER TRIAL INTERIM ANALYSIS
VLU: EpiFix vs. Control % Subjects Complete VLU: Apligraf vs. Control % Subjects Complete
Wound Closure Wound Closure
100% 100%

80% 72% 80%

58% 57%
60% 60%
46%
41% 37% 40%
40% 33% 40% 29%
24% 24%
17% 19%
20% 11% 20% 9% 5%

0% 0%
Week 4 Week 8 Week 12 Week 16 Week 4 Week 8 Week 12 Week 24

EpiFix (N=36) Control (N=37) Apligraf (N=130) Control (N=110)

EpiFix vs. Apligraf VLU Study Results

Note: The MiMedx 100%
90%
control was more 80% 72%
efficacious than the 70%
58% 57%
60%
Apligraf control 50%
33% 37%
40% 29%
Please note: Apligraf and EpiFix studies are 30% Controls: Multi-Layer Compression
17%
independent of one another 20% Therapy with
9%
Apligraf Reference: PMA Supplement 10% EpiFix NuDerm Alginate
(P950032) approval dated 05/22/1998 0% Apligraf Moist Gauze with Zinc
EpiFix Reference: Interim Data Report, Week 4 Week 8 Week 12 Week 16 Week 24 Paste
report dated 11/04/2016
EpiFix (N=36) Apligraf (N=130)

12
 VLU COMMERCIAL COVERAGE IMPACT MODEL

Total EpiFix Commercial Lives DFU/VLU 2015

198,000,000
Currently Uncovered VLU (67%) 132,955,205
6.5M US Patients have
*
VLU Prevalence Rate 0.183%
Chronic Wounds
Additional VLU Patients when Covered 243,696
EpiFix Average Price $1,000
Market Penetration
3M are non-
# of Applications 5% 10.0% 15.0% 20.0%
healing25.0%
wounds 30.0%
1 $ 12,184,780 $ 24,369,560 $ 36,554,340 $ 48,739,119 $ 60,923,899 $ 73,108,679
2 $ 24,369,560 $ 48,739,119 $ 73,108,679 $ 97,478,239 $ 121,847,799 $ 146,217,358
3 $ 36,554,340 $ 73,108,679 $ 109,663,019 $ 146,217,358 $ 182,771,698 $ 219,326,038
4 $ 48,739,119 $ 97,478,239 $ 146,217,358 $ 194,956,478 $ 243,695,597 $ 292,434,717
5 $ 60,923,899 $ 121,847,799 $ 182,771,698 $ 243,695,597 $ 304,619,497 $ 365,543,396

*Under 65 Truven Data

13
 SDS COMPETITIVE PRODUCT COMPARISON

Apligraf and Dermagraft are registered trademarks of Organogenesis, Inc.

Omnigraft and PriMatrix are registered trademarks of Integra Life Sciences Corporation. AMNIOEXCEL is registered trademark of BioD, LLC, an Integra Life Sciences company.
BIOVANCE is a registered trademark of Alliqua Biomedical, Inc.
Grafix is registered trademark of Osiris Therapeutics, Inc.
References provided at end of presentation.
14
 OPERATING ROOM GROWTH TARGET: 5YR 20% CAGR

Operating Room Growth Drivers

1. Increase Footprint
Continue to Hire Direct Surgical Reps,
Currently at 30
Deeper Penetration of GPO and IDN
Contracts

2. Expand Product Line

New Product Launches:
AmnioFill, OrthoFlo LYO
Synergistic Acquisitions

3. Grow Demand
Publish Clinical Trials Showing
Improved Surgical Outcomes and Wound Care Operating Room Pain Management
Reduced Complications
Increase Number of VAC Approvals

15
 TARGET HIGH VALUE SURGICAL PROCEDURES

Number of Procedures (000) Addressable Market Value ($M)

4.3M $5.7B

Orthopedics
Spine, Trauma, Extremities , 2,821
1,528 Sports Medicine

GYN
Hysterectomy, Endometriosis,
$2.9B
1,154 Myomectomy, C-Section, Episiotomy 1,000

PLASTICS
Hand-Tendon and Nerves, Mohs,
652 Scar Revision, Skin Grafting, Surgical 990
Site Dehiscence, Burn
GENERAL COLORECTAL
Bariatric, Fistula Repair,
GI Anastomosis
714 714
UROLOGY
Prostatectomy, Partial Nephrectomy,
237 Cystectomy 200

Source: Millenium Research Group, MRG Lap 2014, ASPS Statistics, MiMedx 2015 Annual Plan, MiMedx internal coding data, Management Estimates
16
 MUSCULOSKELETAL PAIN IS A LARGE OPPORTUNITY

Everyday use Under 361 Regulations Provides the Opportunity

to Generate Revenue while the BLA Process is Ongoing

Wound Care

Operating Room

Pain Management

2017 2018 2019 2020 2021

Knee OA Pain Out of pocket pay 361 Reimbursement opportunity BLA Launch

Plantar Fasciitis Pain Out of pocket pay BLA Launch

17
 2015 U.S. JOINT PAIN INJECTION MARKET

SmartTRAK Business Intelligence and

Company Estimates
18
 TRANSITION TO A BIOPHARMACEUTICAL COMPANY

AmnioFix Injectable (AI) is our Lead Product Candidate

Contains a Milieu of 220+ Proteins
Unified Mechanism of Action
Proven Safety Profile
Covered by our Extensive Placental Tissue Technology Patent Family
Positive Interim Phase llb Data Validates AI Therapeutic Effect in Treating Soft
Tissue Pain, Restoring Function and Improving Quality of Life
First 3 BLAs Target Musculoskeletal Pain
3Q17: Initiate Phase 3 Trial in Plantar Fasciitis
3Q17: Initiate Pivotal Phase 3 Trial in Achilles Tendonitis
3Q17: File IND for Osteoarthritic Knee Pain
4Q17: Initiate Phase 2B Trial in Osteoarthritic Knee Pain
Exiting 2020 Biopharma Sales Approximately 20% of Total Revenue

19
 PLANTAR FASCIITIS PHASE 2B STUDY OUTLINE

A Prospective, Single-Blinded, Randomized Controlled Trial of Micronized

dHACM Injection Compared to Saline Placebo Injection in the Treatment of PF

PURPOSE To determine whether AmnioFix Injectable (mDHACM) is effective in the treatment

of recalcitrant plantar fasciitis

Randomized, Multi-Center, Single-Blind (patient)

DESIGN
147 patients with recalcitrant PF (confirmed diagnosis >1 month and < 18 months,
VAS > 45, conservative usual care > 1 month*)
2-Arm Unilateral Treatment with:
n=73: Placebo (1 ml Normal Saline)
n=74: AmnioFix Injectable (1ml of 40 mg AI)

PRIMARY Mean change in VAS score between baseline and 3 months

Incidence of adverse events at 12 months

SECONDARY Mean change in functional score as measured by FFI-r at 3 months

Immuno-compatibility of first 20 patients followed in each arm at 3 and 12 months
Long Term FFI-R, VAS at 6 and 12 months
20
* Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics
 REPORTED INTERIM PHASE 2B DATA

On the primary efficacy endpoint, pain relief at 3 months, AmnioFix Injectable

demonstrated clinically meaningful and statistically significant separation from
placebo (p-value = 0.0001)

Statistically significant results were generated at 6 months as well (p-value = 0.0005)

80
70
Average VAS Score (SE)

60
50
40
30
20
10
0
Baseline 1 Month 2 Months 3 Months 6 Months
AmnioFix Saline

21
 REPORTED INTERIM PHASE 2B DATA

Note that at the 3 month time point, subjects within the placebo group were
allowed to undergo alternative therapy.

80

70
Average VAS Score (SE)

60

50

40

30

20

10

0
Baseline 1 Month 2 Months 3 Months 6 Months
AmnioFix Saline
22
 REPORTED INTERIM PHASE 2B DATA

The average reduction in pain from baseline over the first 3 months of the study for patients
treated with AmnioFix Injectable was 77.5% (vs. 45.7% for placebo)

Through 6 months post-injection, the average reduction in pain from baseline was 85.9% for
AmnioFix Injectable (vs. 57.1% for placebo). These results unquestionably demonstrate that
AmnioFix Injectable provides a robust pain relief signal
0%
-10%
Percent Reduction from Baseline

-20%
-30%
-40%
-50%
-60%
-70%
-80%
-90%
-100%
Baseline 1 Month 2 Months 3 Months 6 Months
23
AmnioFix Saline
 AI REDUCED THE USE OF OPIOIDS IN PILOT PF STUDY

100%

73.30%

57.10%
50%

26.70%
20%

TRAMADOL USE WEEK 1 TRAMADOL USE WEEK 2

Control 0.5 cc 1.25 cc

2424* Tramadol post injection; week 1 and 2 boot ; week 3 and 4 tennis shoe and limited activity; week 5+ normal activity as tolerated
 PLANTAR FASCIITIS PHASE 3 STUDY OUTLINE

A Prospective, Double-Blinded, Randomized Controlled Trial of Micronized

dHACM Injection Compared to Saline Placebo Injection in the Treatment of PF

PURPOSE To determine whether AmnioFix Injectable (mDHACM) is effective in

the treatment of recalcitrant plantar fasciitis

Randomized, Multi-Center, Double-Blinded (patient)

DESIGN
164 patients with recalcitrant PF (confirmed diagnosis >1 month and <
18 months, VAS > 45, conservative usual care > 1 month*)
2-Arm Unilateral Treatment with:
n=82: Placebo (1 ml Normal Saline)
n=82: AmnioFix Injectable (1ml of 40 mg AI)

PRIMARY Mean change in VAS score between baseline and 3 months

Incidence of adverse events at 6 months

SECONDARY Mean change in functional score as measured by FFI-R at 3 months

Long Term FFI-R and VAS at 6 months

* Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics
25
 ACHILLES TENDONITIS PHASE 3 STUDY OUTLINE

A Prospective, Double-Blinded, Randomized Controlled Trial of Micronized

dHACM Injection Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

PURPOSE To determine whether AmnioFix Injectable (mDHACM) is effective in

the treatment of Achilles tendonitis

Randomized, Multi-Center, Double-Blinded (patient and reviewer)

DESIGN
158 patients with Achilles Tendonitis (confirmed diagnosis >1 month
and < 18 months, VAS > 45, conservative usual care > 1 month*)
2-Arm Unilateral Treatment with:
n=79: Placebo (1 ml Normal Saline)
n=79: AmnioFix Injectable (1ml of 40 mg AI)

PRIMARY Mean change in VAS score between baseline and 3 months

Incidence of adverse events at 6 months

SECONDARY Mean change in functional score as measured by FFI-R at 3 months

Long Term FFI-R and VAS at 6 months

* Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics
26
 A SAFER MORE EFFECTIVE PRODUCT IS NEEDED

*
*

* **

*
*
*
**

* Toxic side effects and limited efficacy ** Limited efficacy

27
 PAIN MANAGEMENT CLINICAL TRIAL MILESTONES

28
 RESPIRATORY AND CARDIOVASCULAR UPDATE

Scanning Electron Microscope

Respiratory System Slides of Respirable Particles
Completing Drug Discovery and
Design Process
Initiating Pre-Clinical Development
Program
Current Goal is to Begin Human
Testing in 4Q 2018

Cardiovascular System
Published Small Animal Study Particle size

Refining Development Program

distribution

Optimizing Delivery System

29
 FINANCIAL HIGHLIGHTS

Q2 2017 Q2 2016 Change YTD 2017 YTD 2016 Change

Revenue $76.4M $57.3M +33% Revenue $149M $110.7M +35%

GM % 88.7% 87.1% +160 bps GM % 88.3% 86.1% +220 bps

Adj. GM* 88.8% 88.1% +70 bps Adj. GM* 88.4% 87.3% +110 bps
R&D % 6.2% 5.5% +70 bps R&D % 6.0% 5.1% +90 bps
S,G&A 72.4% 74.6% -220 bps S,G&A 72.7% 75.4% -270 bps
Net Inc. $8.1M $2.0M +309% Net Inc. $12.4M $3.2M +291%
Adj. NI* $8.2M $5.1M +60% Adj. NI* $15.7M $10.1M +56%
Adj. $14.2M $10.1M +41% Adj. $26.6M $19.1M +39%
EBITDA* EBITDA*

Cash from $13.5M $7.3M +85% Cash from $24.1M $6.3M +283%
Ops Ops

*(non-GAAP)

30
 FINANCIAL HIGHLIGHTS

Revenue
350

300

250

200

150

100

50

0
2014 2015 2016 2017 (Est.)
Wound SSO

2017 Revenue Guidance = $309M - $311M

31
 KEY 2017 MILESTONES

Positive Aetna Coverage Decision

Positive Kaiser Coverage Decision
Presented GI Anastomosis Data
Released Plantar Fasciitis Phase llb Interim Data

Second Half 2017

Initiate Pivotal BLA Phase lll Plantar Fasciitis Trial
Initiate Pivotal BLA Phase lll Achilles Tendonitis Trial
Initiate BLA Phase llb Osteoarthritis Knee Pain Trial
Report VLU Multicenter Data
Report DFU Multicenter Data
Publish GI Anastomosis Data
First Patent Infringement Trial
Additional Reimbursement Wins

32
 REFERENCES

1. http://www.apligraf.com/professional/pdf/FDAApprovalLetter.pdf
2. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p000036
3. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm480564.htm
4. http://www.prnewswire.com/news-releases/derma-sciences-expands-access-of-its-amniotic-tissue-product-line-with-new-premier-inc-agreement-
300024252.html
5. http://www.accessdata.fda.gov/cdrh_docs/pdf8/k083440.pdf
6. http://ir.alliqua.com/press-releases/detail/544/alliqua-to-launch-biovancer-human-amniotic-membrane
7. http://investor.osiris.com/annuals-proxies.cfm; 2011.
8. www.clinicaltrials.gov. Accessed 03/01/17.
9. Zelen CM, Serena TE, Denozire G, Fetterolf DE. A prospective randomized comparative parallel study of amniotic membrane wound graft in the management of
diabetic foot ulcers. Int Wound J. 2013 Oct;10(5):502-7.
10. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion
membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014 Apr;11(2):122-8.
11. Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using
dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic
ulcers. Int Wound J. 2015 Dec;12(6):724-32.
12. Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective,
randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016 Apr;13(2):272-82.
13. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot
ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. (24)2. 2001. pp 290-5.
14. Marston W, Hanft J, Norwood P, Pollak R. The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers. Diabetes Care, Vol 26
#6, June 2000.
15. Driver, V. R., Lavery, L. A., Reyzelman, A. M., Dutra, T. G., Dove, C. R., Kotsis, S. V., Kim, H. M. and Chung, K. C. (2015), A clinical trial of Integra Template for
diabetic foot ulcer treatment. Wound Rep and Reg, 23: 891900. doi:10.1111/wrr.12357.
16. Snyder RJ, Shimozaki K, Tallis A, Kerzner M, Reyzelman A, Lintzeris D, Bell D, Rutan RL, Rosenblum B A Prospective, Randomized, Multicenter, Controlled
Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. Wounds. 2016
Mar;28(3):70-7.
17. Kavros, S; Dutra, T; Gonzalez-Cruz, R; Liden, B; Marcus, B; McGuire, J; Nazario-Guirau, L. The Use of PriMatrix, a Fetal Bovine Acellular Dermal Matrix, in Healing
Chronic Diabetic Foot Ulcers: A Prospective Multicenter Study. Advances in Skin & Wound Care: August 2014 - Volume 27 - Issue 8 - p 356362. doi:
10.1097/01.ASW.0000451891.87020.69.
18. Lavery A, et al. The efficacy and safety of Grafix for treatment of chronic diabetes foot ulcers: results of a multi-centre, controlled, randomized, blinded, clinical
trial. Int Wound J 2014; doi: 10.1111/iwj.12329.
19. Public domain

34